Fig. 6: Anti-angiogenic therapies such as bevacizumab increase VEGF165b protein level and promote the invasive phenotype.

c Representative immunostaining of VEGF165b in H358 subcutaneous xenografts having received, or not, bevacizumab (7.5 mg/kg) once a week. Scale bar = 50 µm.